These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31383751)

  • 1. Correction of Glycogen Synthase Kinase 3β in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice.
    Wang M; Weng WC; Stock L; Lindquist D; Martinez A; Gourdon G; Timchenko N; Snape M; Timchenko L
    Mol Cell Biol; 2019 Nov; 39(21):. PubMed ID: 31383751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of GSK3β at young age prevents muscle pathology in mice with myotonic dystrophy type 1.
    Wei C; Stock L; Valanejad L; Zalewski ZA; Karns R; Puymirat J; Nelson D; Witte D; Woodgett J; Timchenko NA; Timchenko L
    FASEB J; 2018 Apr; 32(4):2073-2085. PubMed ID: 29203592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy.
    Lutz M; Levanti M; Karns R; Gourdon G; Lindquist D; Timchenko NA; Timchenko L
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1.
    Timchenko L
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GSK3β mediates muscle pathology in myotonic dystrophy.
    Jones K; Wei C; Iakova P; Bugiardini E; Schneider-Gold C; Meola G; Woodgett J; Killian J; Timchenko NA; Timchenko LT
    J Clin Invest; 2012 Dec; 122(12):4461-72. PubMed ID: 23160194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSK3β is a new therapeutic target for myotonic dystrophy type 1.
    Wei C; Jones K; Timchenko NA; Timchenko L
    Rare Dis; 2013; 1():e26555. PubMed ID: 25003008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.
    Ward AJ; Rimer M; Killian JM; Dowling JJ; Cooper TA
    Hum Mol Genet; 2010 Sep; 19(18):3614-22. PubMed ID: 20603324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitriol increases MBNL1 expression and alleviates myotonic dystrophy phenotypes in HSA
    Huang K; Wang DD; Hu WB; Zeng WQ; Xu X; Li QX; Bi FF; Yang H; Qiu J
    J Transl Med; 2022 Dec; 20(1):588. PubMed ID: 36510245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation.
    Kuyumcu-Martinez NM; Wang GS; Cooper TA
    Mol Cell; 2007 Oct; 28(1):68-78. PubMed ID: 17936705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1.
    Wang GS; Kuyumcu-Martinez MN; Sarma S; Mathur N; Wehrens XH; Cooper TA
    J Clin Invest; 2009 Dec; 119(12):3797-806. PubMed ID: 19907076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy.
    Li M; Zhuang Y; Batra R; Thomas JD; Li M; Nutter CA; Scotti MM; Carter HA; Wang ZJ; Huang XS; Pu CQ; Swanson MS; Xie W
    Proc Natl Acad Sci U S A; 2020 Mar; 117(10):5472-5477. PubMed ID: 32086392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel.
    Tang ZZ; Yarotskyy V; Wei L; Sobczak K; Nakamori M; Eichinger K; Moxley RT; Dirksen RT; Thornton CA
    Hum Mol Genet; 2012 Mar; 21(6):1312-24. PubMed ID: 22140091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.
    Wang GS; Kearney DL; De Biasi M; Taffet G; Cooper TA
    J Clin Invest; 2007 Oct; 117(10):2802-11. PubMed ID: 17823658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.
    Wojciechowska M; Taylor K; Sobczak K; Napierala M; Krzyzosiak WJ
    RNA Biol; 2014; 11(6):742-54. PubMed ID: 24824895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1.
    Koshelev M; Sarma S; Price RE; Wehrens XH; Cooper TA
    Hum Mol Genet; 2010 Mar; 19(6):1066-75. PubMed ID: 20051426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
    de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
    Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2.
    Jones K; Jin B; Iakova P; Huichalaf C; Sarkar P; Schneider-Gold C; Schoser B; Meola G; Shyu AB; Timchenko N; Timchenko L
    Am J Pathol; 2011 Nov; 179(5):2475-89. PubMed ID: 21889481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1.
    Salisbury E; Sakai K; Schoser B; Huichalaf C; Schneider-Gold C; Nguyen H; Wang GL; Albrecht JH; Timchenko LT
    Exp Cell Res; 2008 Jul; 314(11-12):2266-78. PubMed ID: 18570922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celf1 regulates cell cycle and is partially responsible for defective myoblast differentiation in myotonic dystrophy RNA toxicity.
    Peng X; Shen X; Chen X; Liang R; Azares AR; Liu Y
    Biochim Biophys Acta; 2015 Jul; 1852(7):1490-7. PubMed ID: 25887157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy.
    Orengo JP; Chambon P; Metzger D; Mosier DR; Snipes GJ; Cooper TA
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2646-51. PubMed ID: 18272483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.